The evaluation to confirm the diagnosis of CUP was standard, and included a complete medical history, physical examination, complete blood counts, chemistry profile, computed tomography (CT) scans of the chest/abdomen/pelvis, and appropriate targeted evaluations of any specific signs or symptoms. Patients with pathologic diagnoses based only on fine needle aspiration biopsy specimens were excluded. This retrospective study was performed after approval by an institutional review board.
Specimen collection
The FFPE biopsy tissue blocks were collected for each patient and sent to Pathwork Diagnostics, Inc, where the Tissue of Origin Test was performed. The site of each biopsy and the sex of the patients were provided; otherwise, the assay was performed and test results produced without incorporation of the clinical characteristics, standard pathology results, or response to treatment.
Assay procedure
Prior to performing the Tissue of Origin Test, the biopsy specimens were examined to ensure that specimens contained at least 60% tumor. RNA was then extracted from the biopsy specimen and processed according to previously published methods [11] . Total RNA was isolated from the biopsy specimen using the FormaPure kit (Agencourt, currently Beckman-Coulter Genomics, Beverly, MA) [11] . The total RNA was processed to prepare labeled cDNA for hybridization to Pathchip microarrays manufactured by Affymetrix (Santa Clara, CA) with a two-cycle amplification method using the RampUP kit (Genisphere, Hatfield, PA). A positive/negative total RNA control was run with every amplification batch. The microarrays were washed and stained using the GeneChip Hybridization Wash and Stain kit in a GeneChip Fluidics Station FS450Dx, and scanned with a Gene Chip Scanner 3000Dx (Affymetrix).
The Tissue of Origin Test algorithm transforms probe-level intensity data into gene expression values. The algorithm then performs data verification, standardization and classification in order to generate a test result [7] . Expression levels of the 2000 genes for each specimen are then compared in pairwise fashion with the pre-established gene profiles for each of the 15 tissues on the test panel. The results are reported on an electronic report as 15 separate Similarity Scores, one for each tissue on the panel. The Similarity Score (SS) is a measure of the similarity of the RNA expression pattern of the indicated tumor tissue. Similarity Scores range from 0 (very low similarity) to 100 (very high similarity) and sum to 100 across all 15 tissues on the panel. The highest SS indicates the likely tissue of origin, with one exception: in male patients, a highest SS for ovarian, followed by a second highest SS for testicular germ cell, corresponds to testicular germ cell cancer. A Similarity Score of 5 or less rules out that tissue type as the likely tissue of origin.
For each biopsy specimen, the Tissue of Origin Test result was made available and was then correlated with available clinical, laboratory, and pathology results for each patient. In addition, biopsy specimens from these 48 patients were previously tested with the Veridex 10-gene CUP assay [12] . In this assay, 10 genes are tested using RT-PCR methods, allowing the identification of 6 tumor types (lung, breast, ovary, colon, pancreas, prostate) [8] . Although the Tissue of Origin Test and the Veridex 10-gene assay were not performed in parallel, biopsy material for both assays was obtained from the same archival tissue blocks, so that tissue and source quality was very similar.
Results

Patient characteristics
The Tissue of Origin assay was successfully performed on specimens from 45 of 48 patients (94%). For three patients, the microarray data file did not pass data quality control, and hence reports were not generated. Table 1 summarizes the clinical characteristics of the 45 patients assayed. In general, characteristics are typical of a patient population with CUP. The median age was 56 years; most patients had adenocarcinoma or poorly differentiated adenocarcinoma, and metastases commonly involved the liver, lung, and lymph nodes. The overall response rate to standard empiric chemotherapy regimens for CUP was 20%.
Results of molecular profiling
The sites of origin predicted by the Tissue of Origin test are listed in Table 2 . Most of the common predictions (lung, pancreas, colon, and ovary) are consistent with the array of primary sites identified in historical autopsy series [11] . The identification of 6 sarcomas (all with light microscopic diagnoses of carcinoma or adenocarcinoma) was unexpected, as sarcomas are not usually identified as a substantial fraction of cancers of unknown primary. Also shown in Table 2 are the predictions made by the Veridex 10-gene assay in the same group of patients. In contrast to the Tissue of Origin test, a group of 19 patients (42%) remained undiagnosed by the Veridex assay, perhaps because this assay allowed identification of only 6 primary sites. Veridex assay predictions of lung, pancreas, and colon primaries accounted for 47% of the group, similar to the proportion identified by the Tissue of Origin test.
Comparisons of the assay results for the 24 patients given specific diagnoses by the Veridex 10-gene assay are detailed in Tables 3,4 , and 5. These tables also contain the results of standard pathologic evaluation, clinical features, and results of treatment for each patient. Non-small cell lung cancer was the most common prediction by both assays (Table 3) . In 6 patients, the assays were in agreement, with both assays predicting non-small cell lung cancer. Clinical and pathologic features in these patients were generally compatible with the diagnoses of non-small cell lung cancer, although one patient had a complete response to treatment and an unusually long survival of 65 months. Non-small cell lung cancer was predicted in an additional 9 patients by either the Tissue of Origin test (5 patients) or the Veridex 10-gene assay (4 patients). In each of these cases, other predictions were made by the remaining assay (Table 3 ). Unfortunately, due to the retrospective nature of this study, immunohistochemical characterization of these tumors was inconsistent and often incomplete. Therefore, correlation of these mismatched assay predictions with standard IHC evaluation is not possible.
Similar inconsistencies in assay prediction were common in patients with colorectal, ovary, and pancreas diagnoses (Table 4 and Table 5 ). A total of 7 patients had colorectal cancer predicted by at least 1 assay. Although all 7 patients had predominantly intraabdominal metastases, only 1 patient had colon cancer predicted by both assays (IHC studies in this patient were also typical of colon cancer). As a group, these patients had poor response to empiric treatment for carcinoma of unknown primary, and none received colon cancer-specific regimens. Of the 6 patients with ovarian cancer predictions, only 2 patents had the prediction made by both assays. In general, clinical characteristics of these patients were unusual for ovarian cancer, with a predominance of lung and liver metastases. diagnoses by the Tissue of Origin test. In these patients, histologic diagnoses included poorly differentiated carcinoma (4 patients) and adenocarcinoma (2 patients). The 4 patients with histologic diagnoses of poorly differentiated carcinoma had IHC stains performed; 3 of 4 had one or more cytokeratin markers, while the fourth had staining suggestive of sarcoma (vimentin+, synaptophysin+, CD117+). The Veridex assay predicted ovarian cancer in 1 patient, but in the other 5 patients predicted either "other" (4 patients) or was unsuccessful (1 patient).
Discussion
Recognition of tissue-specific patterns of gene expression provides a potential new diagnostic method for determining the tissue of origin in patients with carcinoma of unknown primary site. Several assays have been developed to predict the tissue of origin by assaying the expression of varying numbers of key genes in a tumor biopsy specimen. When applied to metastatic tumor tissue in patients with cancers of known primary, these assays can correctly identify the tissue of origin in 76-89% of cases [7, 8, [13] [14] [15] [16] groups of patients with carcinoma of unknown primary site, molecular assays provided a putative diagnosis in the majority of patients [7, 12, [17] [18] [19] . In general, these predictions were consistent with clinical features and with the results of standard pathologic evaluation. However, confirmation that the assay predictions were "correct" has been impossible in the majority of patients, since the actual primary site usually remains unidentified. In one small series, the correct primary site was predicted by assay of the original biopsy in 15 of 20 patients with an initial CUP diagnosis who subsequently had primary sites detected during their clinical course [20] .
In spite of these promising results from early studies, the role of molecular tumor profiling in the diagnosis of patients with CUP remains undefined. The relative merits of molecular profiling as compared to standard pathologic evaluation have not been completely defined. Should molecular profiling be performed in the evaluation of every patient with CUP, or are there certain subsets particularly likely to benefit? Should it replace part of the standard pathologic evaluation, such as IHC staining? Is one of the currently available molecular assays more accurate, and therefore "better" than others? The other important unanswered questions relate to the impact of molecular diagnosis on outcome of patient treatment. Can treatment be selected based on molecular profiling predictions? Will that treatment be more effective than empiric CUP regimens or regimens selected based on IHC predictions?
In the study reported here, the Tissue of Origin test was performed on biopsies from a large group of patients with CUP. The important results of this study are as follows: 1) the assay was successfully performed on these archival paraffinized, formalin-fixed biopsies in 45 of 48 cases (94%), 2) in 43 of 45 successfully performed assays, a tissue of origin was predicted; 3) the most common predictions (nonsmall cell lung, pancreas) are consistent with the most common occult primary sites identified in previous autopsy series, and 4) clinical features and routine pathology results in most cases were consistent with the molecular assay predictions. Patients given the diagnosis of ovarian cancer were an exception: in these 5 patients, clinical features were atypical with prominent metastases in the lungs and liver. Another unexpected result was the prediction of 6 patents with sarcoma, most of whom did not have this diagnosis suggested by routine pathology.
Since all biopsies in this series had been previously tested with the Veridex 10-gene assay, this study provided the first opportunity to compare the predictions from 2 molecular profiling assays in a group of CUP patients. As expected, the Tissue of Origin test was able to make a prediction in a higher percentage of cases (96% versus 53%), due at least in part to the Veridex assay's ability to recognize only 6 tumor types. However, agreement between the assays was relatively poor, even when both rendered a prediction (Tables 3-6 ). When lung, colon, or ovarian cancer was predicted, the two assays were in agreement less than 50% of the time. While the methodology of this retrospective study does not allow a determination of which assay was "correct" more frequently, the large number of genes assayed by the Tissue of Origin test suggests that identification of complex patterns of tissue-specific gene expression would be much more likely identified. Conversely, the assay of only 10 genes by the Veridex assay (with the detection of some tumor types reliant on only one gene assayed) is less likely to be specific.
Additional evaluation of the Tissue of Origin test and other "second generation" molecular assays currently available is necessary to define their role in the management of patients with CUP. Although retrospective studies and anecdotal cases suggest the value of these assays in diagnosis and treatment planning, additional clinical studies are urgently needed. The impact of these assays on treatment results is most likely to be detectable in subsets of patients for whom standard site-specific treatment differs from the empiric CUP regimens currently in use (e.g. colorectal cancer, renal cell carcinoma). Demonstration of superior outcome with site-specific treatment in patients given these diagnoses by molecular assay would provide strong rationale for their incorporation into the standard diagnostic evaluations of CUP. Although immediate improvement in treatment results for other subsets (e.g. pancreas, non-small cell lung cancer) is unlikely, even if correctly identified by assay, accurate identification would allow these groups to benefit as therapy for these malignancies improves in the future. Table 6 : Clinicopathologic Characteristics of Patients with Sarcoma Predictions (n = 6).
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